Oseltamivir (Tamiflu®) increases dopamine levels in the rat medial prefrontal cortex

Neuroscience Letters

Volumn 438, Issue 1, 2008, Pages 67-69

  Yoshino, Tatsuki ^a   Nisijima, Koichi ^a   Shioda, Katsutoshi ^a   Yui, Kunio ^b   Kato, Satoshi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Ashiya University   (Japan)

Author keywords

Abnormal behaviors; Dopamine; Medial prefrontal cortex; Oseltamivir; Rat

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; HOMOVANILLIC ACID; OSELTAMIVIR; SEROTONIN; ANTIVIRUS AGENT; ENZYME INHIBITOR;

ABNORMAL BEHAVIOR; ARTICLE; CONTROLLED STUDY; DOPAMINE METABOLISM; DRUG EFFECT; MALE; MICRODIALYSIS; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SEROTONIN METABOLISM; AGE; ANIMAL; CHEMICALLY INDUCED DISORDER; EXTRACELLULAR FLUID; MENTAL DISEASE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNAPTIC TRANSMISSION; UPREGULATION; WISTAR RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; AGE FACTORS; ANIMALS; ANTIVIRAL AGENTS; DOPAMINE; ENZYME INHIBITORS; EXTRACELLULAR FLUID; HOMOVANILLIC ACID; MALE; MENTAL DISORDERS; MICRODIALYSIS; OSELTAMIVIR; PREFRONTAL CORTEX; RATS; RATS, WISTAR; SEROTONIN; SYNAPTIC TRANSMISSION; UP-REGULATION;

EID: 43549116068     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.04.011     Document Type: Article

References (17)

1. Drinka P.J., and Haupt T. Emergence of rimantadine-resistant virus within 6 days of starting rimantadine prophylaxis with oseltamivir treatment of symptomatic cases. J. Am. Geriatr. Soc. 55 (2007) 923-926
2. Ferguson N.M., Cummings D.A., Fraser C., Cajka J.C., Cooley P.C., and Burke D.S. Strategies for mitigating an influenza pandemic. Nature 442 (2006) 448-452
3. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41 (1991) 1-24
4. Handley S.L., McBlane J.W., Critchley M.A., and Njung'e K. Multiple serotonin mechanisms in animal models of anxiety: environmental, emotional and cognitive factors. Behav. Brain Res. 58 (1993) 203-210
5. He G., Massarella J., and Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. 37 (1999) 471-484
6. Izumi Y., Tokuda K., O'dell K.A., Zorumski C.F., and Narahashi T. Neuroexcitatory actions of Tamiflu and its carboxylate metabolite. Neurosci. Lett. 426 (2007) 54-58
7. Lee V.J., Phua K.H., Chenm M.I., Chow A., Ma S., Goh K.T., and Leo Y.S. Economics of neuraminidase inhibitor stockpiling for pandemic influenza, Singapore. Emerg. Infect. Dis. 12 (2006) 95-102
8. Marsden C.A. Dopamine: the rewarding years. Br. J. Pharmacol. 147 Suppl. 1 (2006) S136-S144
9. McGeer A.J., Lee W., Loeb M., Simor A.E., McArthur M., Green K., Benjamin J.H., and Gardner C. Adverse effects of amantadine and oseltamivir used during respiratory outbreaks in a center for developmentally disabled adults. Infect. Control Hosp. Epidemiol. 25 (2004) 955-961
10. Morimoto K., Nakakariya M., Shirasaka Y., Kakinuma C., Fujita T., Tamai I., and Ogihara T. Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein. Drug Metab. Dispos. 36 (2008) 6-9
11. Nakamura M., Yamanaka G., Kawashima H., Watanabe Y., Ioi H., Kashiwagi Y., Takekuma K., Hoshika A., Hayakawa M., and Suzuki S. Clinical application of rapid assay of interleukin-6 in influenza-associated encephalopathy. Dis. Mark. 21 (2005) 199-202
12. Nicholson K.G., Aoki F.Y., Osterhaus A.D., Trottier S., Carewicz O., Mercier C.H., Rode A., Kinnersley N., and Ward P. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 355 (2000) 1845-1850
13. Nisijima K., Kashiwa A., Hashimoto A., Iwama H., Umino A., and Nishikawa T. Differential effects of phencyclidine and methamphetamine on dopamine metabolism in rat frontal cortex and striatum as revealed by in vivo dialysis. Synapse 22 (1996) 304-312
14. Noor R., Wang C.X., and Shuaib A. Hyperthermia masks the neuroprotective effects of tissue plaminogen activator. Stroke 36 (2005) 665-669
15. Weisstaub N.V., Zhou M., Lira A., Lambe E., González-Maeso J., Hornung J.P., Sibille E., Underwood M., Itohara S., Dauer W.T., Ansorge M.S., Morelli E., Mann J.J., Toth M., Aghajanian G., Sealfon S.C., Hen R., and Gingrich J.A. Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science 313 (2006) 536-540
16. Yoshino T., Nisijima K., Shioda K., Yui K., and Katoh S. Perospirone, a novel atypical antipsychotic drug, potentiates fluoxetine-induced increases in dopamine levels via multireceptor actions in the rat medial prefrontal cortex. Neurosci. Lett. 364 (2004) 16-21
17. Yoshino T., Nisijima K., Katoh S., Yui K., and Nakamura M. Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT (1A) receptors in the rat medial frontal cortex. Neurochem. Int. 40 (2002) 355-360